A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes

Autor: Stephen A. Harrison, Nadege Gunn, Guy W. Neff, Anita Kohli, Liping Liu, Abbey Flyer, Lawrence Goldkind, Adrian M. Di Bisceglie

Publikováno v: Nature Communications, Vol 12, Iss 1, Pp 1-8 (2021)

Berberine ursodeoxycholate has been studied for its serum lipid and lipoprotein lowering effects. Here the authors report an 18-week phase 2, randomised, double-blind, placebo-controlled clinical trial that tested the effect of berberine ursodeoxycho

Externí odkaz: https://doaj.org/article/13c7aeb937eb489ca602dac9be76c850

Review: Predicting the probable outcome of treatment in HCV patients

Autor: Udayakumar Navaneethan, Nyingi Kemmer, Guy W. Neff

Publikováno v: Therapeutic Advances in Gastroenterology, Vol 2 (2009)

Hepatitis C virus (HCV) is a major cause of chronic liver disease infecting more than 170 million people worldwide. HCV produces a wide gamut of manifestations varying from mild self-limiting disease to cirrhosis and hepatocellular carcinoma. A varie

Externí odkaz: https://doaj.org/article/5708f0b418444ba6b6c31b8b21651f8c

Biomarkers, Imaging, and Safety in a Well-compensated NASH Cirrhotic Cohort Treated With Resmetirom, a Thyroid Hormone Receptor-beta Selective Agonist, for 52 Weeks

Autor: Jörn Schattenberg, KrisV. Kowdley, Rebecca A. Taub, Naim Alkhouri, Guy W. Neff, Stephen A. Harrison

Publikováno v: 39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8689796d2bb94ad43d6064d4e3db2f93
https://doi.org/10.1055/s-0042-1759975

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Autor: Guy W. Neff, Timothy P Rolph, Erik J. Tillman, Andrew T. A. Cheng, Chen Hu, Rashmee Patil, Bradley Freilich, Peter Ruane, Stephen A. Harrison, Cynthia Behling, Erica Fong, Brittany De Temple, Kitty Yale

Publikováno v: Nature Medicine. 27:1262-1271

Preclinical and clinical data suggest that fibroblast growth factor 21 (FGF21) is anti-fibrotic, improves metabolic status and has potential to treat non-alcoholic steatohepatitis (NASH). We assessed the safety and efficacy of efruxifermin, a long-ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ccfb2cc3d3735e095c238b8d43393935
https://doi.org/10.1038/s41591-021-01425-3

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis

Autor: Fernando Membreno, Giuseppe Morelli, Ray Thomason, Kalyan Ram Bhamidimarri, Dawn Torres, Andrew Scanga, Danielle Brandman, Guy W. Neff, Mark McKenzie, Stephen H. Caldwell, Kathleen E. Corey, Nadeem Anwar, Kimberly A. Brown, James Strobel, Sammy Saab, Thomas Amankonah, Bal R. Bhandari, Souvik Sarkar, Don C. Rockey, Miguel Á. Rodríguez, Mazen Noureddin, Edward Mena, Nikolaos Pyrsopoulos, Ayman Koteish, Gary A. Abrams, Andrew DeLemos, Richard Frederick, Bhaktasharan Patel, David T. Hagerty, Amy Stratton, Kathryn J. Lucas, Ethan M. Weinberg, Zeid Kayali, Anita Kohli, Marina Roytman, Kris V. Kowdley, Nicole Wedick, Brett E. Fortune, Michael P. Curry, Sofia Jakab, Kiran Bambha, Satinder Gill, Stevan A. Gonzalez, Nikunj Shah, Warren N. Schmidt, Jean L. Chan, Charles S. Landis, Bradley Freilich, Catherine Frenette, Hugo E. Vargas, Mary E. Rinella, Mohammad S. Siddiqui, Andrew P. Keaveny, George Therapondos, Elizabeth C. Verna, Ray Kim, James M. Robinson, David I. Bernstein, Marwan Ghabril, Reem Ghalib, John M. Vierling, Manal F. Abdelmalek, Paul J. Thuluvath, Jen-Jung Pan, Ravi Ravendhran, Amanda Wieland, Eric Lawitz, Justin Reynolds, Victor Ankoma-Sey, Mitchell L. Shiffman, Nyingi Kemmer, William M. Lee, Viviana Figueroa-Diaz, Douglas A. Simonetto, Jonathan Huang, Aasim Sheikh, Parvez S. Mantry, Harvey Tatum, Lance Stein

Publikováno v: Journal of hepatology. 74(2)

Background & Aims Non-alcoholic steatohepatitis is a leading cause of end-stage liver disease. Hepatic steatosis and lipotoxicity cause chronic necroinflammation and direct hepatocellular injury resulting in cirrhosis, end-stage liver disease and hep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76272acaeb30d8a655a783c8511b9b83
https://pubmed.ncbi.nlm.nih.gov/33038432